Human CEACAM-6/CD66c Alexa Fluor® 647-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB3934R
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Lys35-Gly320
Accession # P40199
Specificity
Clonality
Host
Isotype
Applications for Human CEACAM-6/CD66c Alexa Fluor® 647-conjugated Antibody
Flow Cytometry
Sample: Human whole blood granulocytes and HEK293 human embryonic kidney cell line transfected with human CEACAM-6/CD66c and eGFP
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: CEACAM-6/CD66c
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6), previously called nonspecific cross‑reacting antigen (NCA) or CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily (1-4). In humans, CEACAMs include type I transmembrane proteins (CEACAM-1, -3, and -4) and Glycosylphosphatidylinositol (GPI)-linked molecules (CEACAM-5 through -8) (1). There is no human CEACAM-2. Human CEACAM-6 is a 90 kDa, GPI-linked membrane protein that contains a 34 amino acid (aa) signal sequence, a 286 aa extracellular domain (ECD), and a 24 aa hydrophobic C-terminal propeptide. The GPI membrane anchor is attached at the C-terminus following cleavage of the propeptide. CEACAM-6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains (2-4). It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-Selectin, Galectins and some bacterial fimbrae (1, 2). Mature human CEACAM-6 shows 84%, 85%, 80%, 87% and 51% aa identity to the equivalent extracellular regions of human CEACAMs -1, -5 (CEA) and -8, rhesus CEACAM-2, and bovine CEACAM-6, respectively. CEACAM-6 is expressed by granulocytes and their precursors. Activation enhances surface expression by mobilizing CEACAM-6 from storage in azurophilic granules (5, 6). It often shows aberrant expression in acute lymphocytic leukemias (10). CEACAM-6 is also expressed in epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas and hyperplastic polyps (7, 8). Over-expression confers resistance to adhesion-related apoptosis (anoikis) in tumor cells (8, 9). CEACAM-6 is an intercellular adhesion molecule, forming both homotypic, and heterotypic bonds with CEACAM-1, -5 and -8 through interaction of the V-type Ig-like domains (11, 12). Cross-linking of neutrophil CEACAM-6 augments Integrin alphav beta3 and beta2-mediated adhesion, apparently by Src and Caveolin-mediated inside-out Integrin activation (8, 13, 14).
References
- Beauchemin, N. et al. (1999) Exp. Cell Res. 252:243.
- Skubitz, K.M. et al. (1999) J. Biol. Regul. Homeost. Agents 13:244.
- Barnett, T. et al. (1988) Genomics 3:59.
- Tawaragi, Y. et al. (1988) Biochem. Biophys. Res. Comm. 150:89.
- Kuroki, M. et al. (1995) Immunol. Invest. 24:829.
- Ducker, T.P. and K.M. Skubitz (1992) J. Leukoc. Biol. 52:11.
- Scholzel, S. et al. (2000) Am. J. Pathol. 156:595.
- Duxbury, M.S. et al. (2004) J. Biol. Chem. 279:23176.
- Ilantzis, C. et al. (2002) Neoplasia 4:151.
- Kalina, T. et al. (2005) BMC Cancer 5:38.
- Oikawa, S. et al. (1992) Biochem. Biophys. Res. Commun. 186:881.
- Kuroki, M. et al. (2001) J. Leukoc. Biol. 70:543.
- Duxbury, M.S. et al. (2004) Biochem. Biophys. Res. Comm. 317:133.
- Skubitz, K.M. et al. (1999) J. Leukoc. Biol. 60:106.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional CEACAM-6/CD66c Products
Product Documents for Human CEACAM-6/CD66c Alexa Fluor® 647-conjugated Antibody
Product Specific Notices for Human CEACAM-6/CD66c Alexa Fluor® 647-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only